Navigation Links
American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
Date:11/15/2009

Study highlights:

- Used during coronary angioplasty plus stenting, in patients who all received clopidogrel after the procedure, a new reversible blood thinner did not have a significantly different effect from placebo on the composite endpoint of all-cause mortality, heart attack and need for new procedures to reopen coronary arteries.

- However, the investigational drug significantly lessened the risk for two pre-specified single secondary endpoints: all-cause mortality and in-stent blood clots.

ORLANDO, Fla., Nov. 15 /PRNewswire-USNewswire/ -- A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

CHAMPION PLATFORM, a phase III trial, included 5,362 angioplasty-plus-stent patients randomized to receive either a placebo or the investigational drug cangrelor during procedures to reopen coronary artery blockages. Cangrelor is a potent, fast-acting and reversible anti-clotting drug delivered intravenously.

After their procedures, all patients received 600 milligrams (mg) of the oral, nonreversible anti-clotting drug clopidogrel, which is routinely used in such procedures.

The trial, which enrolled patients beginning in 2006, ended when an interim review committee concluded that cangrelor would fail to show superiority over clopidogrel for its primary endpoint: a composite of all-cause death, heart attack and the need for coronary revascularization procedures.

"There was no statistically significant difference between the two arms of the trial at our 48-hour endpoint," said Deepak L. Bhatt, M.D., M.P.H., chief of cardiology at the VA Boston Healthcare System. "However, a number of secondary endpoints had very interesting and informative findings. For instance, all-cause death as a stand-alone endpoint was reduced significantly from 0.7 percent in controls to 0.2 percent (67% reduction) in the cangrelor group.

"It is intriguing, of course, but it is a secondary endpoint and needs to be interpreted with some caution given that the primary endpoint was not met and the number of deaths overall was low."

Furthermore, acute stent thrombosis (blood clots that form within the stent) was significantly reduced in the test group.

"That's something that interventional cardiologists really worry about because stent thrombosis is often associated with a recurrent heart attack or death," said Bhatt, who is also director of the integrated interventional cardiovascular program at Brigham and Women's Hospital and the VA Boston Healthcare System and a faculty member at Harvard Medical School in Boston, Mass. "Acute stent thrombosis was reduced from 0.6 percent in controls to 0.2 percent in the test group (69% reduction), again a significant benefit. So there seems to be a plausible mechanism by which mortality may have been reduced since stent thrombosis was reduced."

Researchers found no difference in endpoints between test and control groups for severe bleeding and need for blood transfusion. However, less severe bleeding was significantly higher with the new agent, 5.4 percent vs. 3.4 percent in controls, an indication of the investigational drug's potency, Bhatt said. Because it's reversible and is delivered through an intravenous line, bleeding events can be ended quickly after the drug is no longer administered.

Clopidogrel is given orally and is irreversible -- once it binds to a platelet it remains for the life of that blood cell, usually 7 to 10 days. That puts clopidogrel patients at higher risk of bleeding complications if they need emergency surgery, he said.

"At least in theory, cangrelor has all the attributes that an interventional cardiologist would want: Its onset of action is very quick and it's very potent, but on the back end you can turn it off," Bhatt said.

The companion CHAMPION PCI trial, which had a different patient group and slightly different hypothesis, was presented at the same session.

The Medicines Company funded the study.

Co-authors of the study are the CHAMPION executive committee members.

Disclosure: Dr. Bhatt receives grant support from the study sponsor.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

NR09 - 1161 (SS09/CHAMPION PLATFORM Bhatt)

SOURCE American Heart Association


'/>"/>
SOURCE American Heart Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference
2. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
3. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
4. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
5. American Oriental Bioengineering to Report Third Quarter 2009 Financial Results on November 16, 2009
6. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
7. California American Water Celebrates No Drugs Down the Drain Week in San Diego
8. VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
9. American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials
10. Educational Video Series Released for American Diabetes Month
11. CyberKnife to be Focus of Numerous Presentations at the American Society for Radiation Oncology (ASTRO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Progra m m e ... Oxitec , s mosquito in Cayman Islands ... by 96 %   Oxitec and the Cayman ... wild Aedes aegypti, the dangerous mosquito that spreads dengue, Zika and ... Grand Cayman .  MRCU, a global leader in mosquito control, is ...
(Date:5/5/2016)... , May 5, 2016 /PRNewswire/ ... announced the addition of the  "Europe ... - 2016"  report to their offering.  ... ) , ,The latest research ... Highlights - 2016, provides comprehensive insights ...
(Date:5/4/2016)... May 4, 2016  Compass Diversified Holdings (NYSE: ... an owner of leading middle market businesses, announced today ... March 31, 2016. First Quarter 2016 Highlights ... Reinvestment ("CAD" or "Cash Flow") of $13.6 million for ... loss of $15.0 million for the first quarter of ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... , ... TLC Laser Eye Centers announced today that it has acquired Gordon ... be called “Gordon Schanzlin New Vision Institute, a TLC Laser Eye Center.” , ... ensure that patients continue to receive the highest quality of care. In addition, all ...
(Date:5/5/2016)... ... 05, 2016 , ... LELO has discovered many people are insecure ... out via email, social media and on the Volonté blog seeking advice about how ... masturbate ‘normal’ or ‘correct’?” , While some methods are more common than others, there ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... master charity program created to assist the people of their local community. The ... nonprofit organizations and community leaders. Their hope is to bring awareness to important ...
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has ... Awards, presented by the American Institute of Architects and the Academy of Architecture for ... renowned Perkins+Will and Harrell Architects, opened to patients in October of 2014. ...
(Date:5/5/2016)... ... 2016 , ... Sun Health registered nurse Brittany Eads and ... Care Transitions program at the 9th Annual Orthopedic and Spine Summit held ... Post-Acute Environment Through Effective Transitions of Care.” , Major changes are taking place ...
Breaking Medicine News(10 mins):